Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Mereo Biopharma Group Plc (0A9G) AI Stock Analysis

Top Page

GB:0A9G

Mereo Biopharma Group Plc

(LSE:0A9G)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverageMinimal debt limits solvency pressure and preserves financial flexibility relative to more highly leveraged biotech peers. This gives Mereo greater capacity to direct capital toward clinical development and partnerships, although it does not eliminate the need for future funding.
Negative Factors
Near-zero revenue and persistent lossesThe absence of meaningful current revenue leaves Mereo dependent on future clinical success, licensing proceeds, or external financing rather than operating income. Persistent large losses reduce financial resilience and make the business model highly sensitive to development outcomes and funding access.

Mereo Biopharma Group Plc (0A9G) vs. iShares MSCI United Kingdom ETF (EWC)

-100%-75%-50%-25%0%25%50%GB:0A9G-84.02%EWC+21.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$46.23M
Dividend Yield
―
Average Volume (3M)
123.57K
Price to Earnings (P/E)
-1.6
Beta (1Y)
0.61
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
39
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Mereo Biopharma Group Plc Business Overview & Revenue Model

Company Description

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the c...

Mereo Biopharma Group Plc Risk Analysis

Mereo Biopharma Group Plc disclosed 73 risk factors in its most recent earnings report. Mereo Biopharma Group Plc reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Mereo Biopharma Group Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A9G against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GANXGANX48Neutral$49.32M-2.26-161.58%――23.02%
MISTMIST46Neutral$90.88M-1.06-288.36%――21.42%
CRVOCRVO42Neutral$24.19M-0.50-156.02%―-95.74%-23.18%
ANVSANVS40Underperform$48.23M-0.63-685.96%――11.96%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%GB:0A9GCRVOMISTANVSGANXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
GB:0A9G and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A9GMereo Biopharma0.29-1.55-84.29%
CRVOCervomed Inc.1.60-5.42-77.21%
MISTMilestone Pharmaceuticals0.73-1.12-60.54%
ANVSAnnovis Bio Inc1.13-0.89-44.06%
GANXGain Therapeutics, Inc.1.13-0.71-38.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.